CA3063622A1 - Anti-sirp.alpha. antibodies - Google Patents
Anti-sirp.alpha. antibodies Download PDFInfo
- Publication number
- CA3063622A1 CA3063622A1 CA3063622A CA3063622A CA3063622A1 CA 3063622 A1 CA3063622 A1 CA 3063622A1 CA 3063622 A CA3063622 A CA 3063622A CA 3063622 A CA3063622 A CA 3063622A CA 3063622 A1 CA3063622 A1 CA 3063622A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- cdr1
- cdr2
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17171285 | 2017-05-16 | ||
| EP17171285.4 | 2017-05-16 | ||
| PCT/EP2018/062473 WO2018210793A2 (en) | 2017-05-16 | 2018-05-15 | ANTI-SIRPα ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3063622A1 true CA3063622A1 (en) | 2018-11-22 |
Family
ID=58714966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3063622A Pending CA3063622A1 (en) | 2017-05-16 | 2018-05-15 | Anti-sirp.alpha. antibodies |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11274159B2 (https=) |
| EP (2) | EP3625259B1 (https=) |
| JP (1) | JP7171617B2 (https=) |
| KR (1) | KR102714600B1 (https=) |
| CN (2) | CN118271443A (https=) |
| AR (1) | AR111630A1 (https=) |
| AU (1) | AU2018268304B2 (https=) |
| BR (1) | BR112019023754A2 (https=) |
| CA (1) | CA3063622A1 (https=) |
| CL (1) | CL2019003266A1 (https=) |
| DK (1) | DK3625259T3 (https=) |
| ES (1) | ES2981193T3 (https=) |
| FI (1) | FI3625259T3 (https=) |
| HR (1) | HRP20240924T1 (https=) |
| HU (1) | HUE067040T2 (https=) |
| LT (1) | LT3625259T (https=) |
| MX (1) | MX2019013749A (https=) |
| MY (1) | MY199247A (https=) |
| PL (1) | PL3625259T3 (https=) |
| PT (1) | PT3625259T (https=) |
| RU (1) | RU2771174C2 (https=) |
| TW (1) | TWI710574B (https=) |
| WO (2) | WO2018210793A2 (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66062B1 (sr) | 2016-04-14 | 2024-11-29 | Ose Immunotherapeutics | Nova anti-sirpa antitela i njihove terapijske primene |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| CN118027200A (zh) | 2016-12-09 | 2024-05-14 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| CN118267470A (zh) * | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| MX2020009774A (es) | 2018-03-21 | 2020-10-08 | Alx Oncology Inc | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. |
| EP3802602A1 (en) | 2018-05-25 | 2021-04-14 | Alector LLC | Anti-sirpa antibodies and methods of use thereof |
| CN112384532B (zh) * | 2018-06-29 | 2025-01-10 | 艾利妥 | 抗SIRP-β1抗体及其使用方法 |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| SG11202102851XA (en) | 2018-09-27 | 2021-04-29 | Celgene Corp | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
| CA3118966A1 (en) * | 2018-11-15 | 2020-05-22 | Byondis B.V. | Humanized anti-sirpa antibodies |
| CN114206912B (zh) | 2019-06-07 | 2025-02-11 | Alx肿瘤生物技术公司 | 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂 |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| KR20220091576A (ko) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
| AU2020394204A1 (en) | 2019-11-27 | 2022-06-02 | ALX Oncology Inc. | Combination therapies for treating cancer |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| JP7437815B2 (ja) | 2019-12-24 | 2024-02-26 | ラノバ メディシンズ リミテッド | 抗ＳＩＲＰαモノクローナル抗体およびその使用 |
| KR20260017503A (ko) | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| WO2021226591A1 (en) * | 2020-05-08 | 2021-11-11 | Electra Therapeutics, Inc. | Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof |
| US12343377B2 (en) | 2020-06-01 | 2025-07-01 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
| CN114560940B (zh) * | 2020-11-27 | 2023-07-14 | 缔码生物科技(武汉)有限公司 | 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用 |
| JP7663265B2 (ja) * | 2020-11-30 | 2025-04-16 | クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド | 抗ＳＩＲＰα抗体またはその抗原結合断片および適用 |
| WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| CN112574310B (zh) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| BR112023025194A2 (pt) * | 2021-06-04 | 2024-02-27 | Boehringer Ingelheim Int | Anticorpos anti-sirp-alfa |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023020459A1 (zh) * | 2021-08-17 | 2023-02-23 | 杭州九源基因工程有限公司 | 靶向SIRPα的单克隆抗体及其用途 |
| AU2022337223A1 (en) * | 2021-09-03 | 2024-04-11 | Zymeworks Bc Inc. | Fc variant with high thermal stability and attenuated effector function |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| JP2025523369A (ja) | 2022-06-01 | 2025-07-23 | エーエルエックス オンコロジー インコーポレイテッド | 尿路上皮癌腫を治療するための併用療法 |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4619435A1 (en) | 2022-11-16 | 2025-09-24 | Boehringer Ingelheim International GmbH | Predictive efficacy biomarkers for anti-sirpa antibodies |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220895A1 (en) * | 2023-04-20 | 2024-10-24 | Twist Bioscience Corporation | Antibodies and variant nucleic acid libraries for sirp-alpha |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN116715774B (zh) * | 2023-05-12 | 2023-11-24 | 武汉爱博泰克生物科技有限公司 | 针对人axl的兔单克隆抗体及其制备方法和应用 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN118344476B (zh) * | 2024-05-16 | 2024-11-15 | 武汉爱博泰克生物科技有限公司 | 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用 |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN118620078B (zh) * | 2024-07-09 | 2024-11-19 | 武汉爱博泰克生物科技有限公司 | 抗人cd45ra蛋白的抗体、抗体偶联物及其应用 |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU1701001A (en) | 1999-11-30 | 2001-06-12 | Eberhard-Karls-Universitat Tubingen Universitatsklinikum | Antibodies against signal regulator proteins |
| CN103172731A (zh) | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| RU2597831C2 (ru) * | 2011-01-19 | 2016-09-20 | Кантаргия Аб | Анти-il1rap антитела и их применение при лечении людей |
| WO2013056352A1 (en) * | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| WO2013150043A1 (en) * | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| EP3795215A1 (en) * | 2012-05-30 | 2021-03-24 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| CA2994935A1 (en) * | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
| JP7078533B2 (ja) * | 2015-10-21 | 2022-05-31 | オーエスイー イムノセラピューティクス | 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物 |
| SG11201808465UA (en) | 2016-04-14 | 2018-10-30 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| KR102878970B1 (ko) | 2016-08-03 | 2025-10-30 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴 |
-
2018
- 2018-05-15 CN CN202410367469.2A patent/CN118271443A/zh active Pending
- 2018-05-15 FI FIEP18729328.7T patent/FI3625259T3/fi active
- 2018-05-15 DK DK18729328.7T patent/DK3625259T3/da active
- 2018-05-15 EP EP18729328.7A patent/EP3625259B1/en active Active
- 2018-05-15 RU RU2019141289A patent/RU2771174C2/ru active
- 2018-05-15 JP JP2019563581A patent/JP7171617B2/ja active Active
- 2018-05-15 HU HUE18729328A patent/HUE067040T2/hu unknown
- 2018-05-15 KR KR1020197037055A patent/KR102714600B1/ko active Active
- 2018-05-15 MX MX2019013749A patent/MX2019013749A/es unknown
- 2018-05-15 AU AU2018268304A patent/AU2018268304B2/en active Active
- 2018-05-15 WO PCT/EP2018/062473 patent/WO2018210793A2/en not_active Ceased
- 2018-05-15 TW TW107116450A patent/TWI710574B/zh active
- 2018-05-15 US US16/614,199 patent/US11274159B2/en active Active
- 2018-05-15 LT LTEPPCT/EP2018/062473T patent/LT3625259T/lt unknown
- 2018-05-15 CA CA3063622A patent/CA3063622A1/en active Pending
- 2018-05-15 EP EP24169594.9A patent/EP4400173A3/en active Pending
- 2018-05-15 WO PCT/EP2018/062477 patent/WO2018210795A1/en not_active Ceased
- 2018-05-15 MY MYPI2019006658A patent/MY199247A/en unknown
- 2018-05-15 PL PL18729328.7T patent/PL3625259T3/pl unknown
- 2018-05-15 HR HRP20240924TT patent/HRP20240924T1/hr unknown
- 2018-05-15 ES ES18729328T patent/ES2981193T3/es active Active
- 2018-05-15 CN CN201880032714.7A patent/CN110799536B/zh active Active
- 2018-05-15 PT PT187293287T patent/PT3625259T/pt unknown
- 2018-05-15 BR BR112019023754A patent/BR112019023754A2/pt unknown
- 2018-05-16 AR ARP180101300A patent/AR111630A1/es not_active Application Discontinuation
-
2019
- 2019-11-14 CL CL2019003266A patent/CL2019003266A1/es unknown
-
2022
- 2022-02-02 US US17/591,231 patent/US11718681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3625259B1 (en) | Anti-sirpalpha antibodies | |
| JP7451520B2 (ja) | ヒト化抗ＳＩＲＰα抗体 | |
| US20210040212A1 (en) | Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects | |
| TW202221029A (zh) | 抗cd93之構築體及其用途 | |
| TW202432594A (zh) | 抗ccr8抗體及其用途 | |
| US20220265821A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas | |
| KR102955590B1 (ko) | 인간화 항-SIRPα 항체 | |
| RU2812199C2 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИ-SIRPα АНТИТЕЛА | |
| US20250361320A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
| KR20260044233A (ko) | 항-ceacam5 항체 약물 접합체 | |
| EA052794B1 (ru) | Новые антитела против fgfr2 | |
| TW202210515A (zh) | 抗ｃｄ３９之構築體及其用途 | |
| NZ787254A (en) | Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220729 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240814 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241213 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250207 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250505 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250505 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250611 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250611 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250915 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260204 |